Clinical trialNCT06920043RecruitingPhase 2Interventional

A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

SponsorGlaxoSmithKlineEnrollment42Metabolic Dysfunction-Associated SteatohepatitisNon-alcoholic Fatty Liver Disease

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.

clinicaltrials.gov ↗

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

30 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Gsk Investigational Site
Chandler, Arizona, United States
Anita Kohli
Recruiting
Gsk Investigational Site
Mesa, Arizona, United States
Ann Moore
Recruiting
Gsk Investigational Site
Tucson, Arizona, United States
Aimee Bachelier
Recruiting
Gsk Investigational Site
Fresno, California, United States
Muhammad Sheikh
Recruiting
Gsk Investigational Site
Lancaster, California, United States
Jatinder Pruthi
Recruiting
Gsk Investigational Site
Pasadena, California, United States
Edward Mena
Recruiting
Gsk Investigational Site
Rialto, California, United States
Zeid Kayali
Recruiting
Gsk Investigational Site
Santa Maria, California, United States
Keval Shah
Recruiting
Gsk Investigational Site
Miami, Florida, United States
Lazaro M Garcia
Recruiting
Gsk Investigational Site
Viera, Florida, United States
Rosemary Laird
Recruiting
Gsk Investigational Site
Marietta, Georgia, United States
Aasim Sheikh
Recruiting
Gsk Investigational Site
Baltimore, Maryland, United States
Paul Thuluvath
Recruiting
Gsk Investigational Site
Kansas City, Missouri, United States
Bradley Freilich
Recruiting
Gsk Investigational Site
New York, New York, United States
Frances Lee
Recruiting
Gsk Investigational Site
Fayetteville, North Carolina, United States
John Poulos
Recruiting
Gsk Investigational Site
Wilson, North Carolina, United States
Mitchell Mahmoud
Recruiting
Gsk Investigational Site
Austin, Texas, United States
Nomita Kim
Recruiting
Gsk Investigational Site
Austin, Texas, United States
Rohit Puskoor
Recruiting
Gsk Investigational Site
Austin, Texas, United States
Carmen Landaverde
Recruiting
Gsk Investigational Site
Dallas, Texas, United States
Parvez Mantry →
Recruiting
Gsk Investigational Site
Georgetown, Texas, United States
Nirupama Jerome
Recruiting
Gsk Investigational Site
Houston, Texas, United States
Prasun Jalal
Recruiting
Gsk Investigational Site
Houston, Texas, United States
Joseph Galati
Recruiting
Gsk Investigational Site
Houston, Texas, United States
David Huang
Recruiting
Gsk Investigational Site
Pasadena, Texas, United States
Rukan Daccak
Recruiting
Gsk Investigational Site
Pearland, Texas, United States
Jignesh Shah
Recruiting
Gsk Investigational Site
San Antonio, Texas, United States
Eric Lawitz →
Recruiting
Gsk Investigational Site
San Antonio, Texas, United States
Daniel Santillano
Recruiting
Gsk Investigational Site
Waco, Texas, United States
Gregg Lucksinger
Recruiting
Gsk Investigational Site
Richmond, Virginia, United States
Michael Fuchs
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Efimosfermin alfaPlacebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 9 Apr 2025
Primary completion: 10 Jul 2028
Completion: 10 Jul 2028
Last update posted: 8 Jul 2026
Registered enrollment: 42
Registry id: NCT06920043

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.